Kimberly-Clark Corp. KMB

Kimberly-Clark Corporation se dedica a la fabricación y comercialización de una variedad de productos hechos de fibras naturales o sintéticas utilizando tecnologías en fibras, no tejidos y absorción. Los segmentos de la empresa incluyen Cuidado Personal, que ofrece soluciones y productos como pañales desechables, calzones de entrenamiento y juventud, pañales para nadar, toallitas húmedas para bebés, productos de cuidado femenino e incontinencia, y otros productos relacionados, que se venden bajo las marcas Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise y otras marcas; Productos de Consumo ofrece pañuelos faciales y de baño, toallas de papel, servilletas y productos relacionados, que se venden bajo las marcas Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve y otras marcas, y K-C Professional, que ofrece soluciones y productos de apoyo como paños, tejidos, toallas, ropa, jabones y desinfectantes. Sus marcas incluyen Kleenex, Scott, WypAll, Kimtech y KleenGuard.

Con 11 acciones de KMB (USD 1.037,30) habrías recibido USD 56,10 en dividendos en los últimos 12 meses.

• The Motley Fool 18 sept

  3 Unstoppable Dividend Stocks to Buy Now (1 Yields 5.5%)

  The article highlights three dividend-paying stocks offering yields between 1.6% and 5.5%: Kimberly-Clark (5.2% yield, 54-year dividend growth streak), FedEx (1.6% yield, 17% annual dividend growth), and Realty Income (5.5% yield, 57-year consecutive monthly dividend payments). All three companies are positioned as quality businesses with durable competitive advantages and strong cash flow generation.

  

• The Motley Fool 14 sept

  Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now

  Kenvue (KVUE) is highlighted as a smart high-yield dividend stock with a 4.68% dividend yield and 64 consecutive years of dividend increases, making it a Dividend King. The company, spun off from Johnson & Johnson three years ago, generates steady revenue from recession-resilient consumer healthcare brands like Tylenol and Neutrogena. However, uncertainty exists due to a pending acquisition by Kimberly-Clark (KMB), another Dividend King with a 5.23% yield.

  

• Zacks Investment Research 7 sept

  Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead

  Kenvue has secured shareholder approval and U.S. antitrust clearance for its planned Q4 2026 combination with Kimberly-Clark. However, the deal faces ongoing risks including weak Self Care segment performance, $8.5B debt burden, margin pressures from inflation and tariffs, restructuring costs, and pending litigation. Q2 results showed 3% sales growth but EPS missed estimates with adjusted gross margin declining 70 basis points.

  

• Zacks Investment Research 7 sept

  Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?

  Kenvue Inc. (KVUE) demonstrated improved profitability in the first half of 2026, with adjusted operating margins rising 180 basis points to 23.1% and earnings climbing 18.9%, driven primarily by cost-cutting initiatives. However, organic sales growth remained modest at 1.2%, with the Self Care segment struggling while Skin Health and Beauty showed stronger performance. The company faces headwinds from tariffs, inflation, and $8.5 billion in debt, with a pending merger with Kimberly-Clark expected to close in Q4 2026.

  

• Zacks Investment Research 31 ago

  P&G Fiscal 2027 Outlook Brings an 8% Core EPS Headwind Into Focus

  Procter & Gamble expects fiscal 2027 to face a $1.4 billion after-tax earnings headwind (56 cents per share), driven by $1 billion in higher input costs, increased financing expenses, lower non-operating income, and unfavorable currency. Despite 1-3% expected organic sales growth, the company projects flat to 3% core EPS growth, relying on productivity improvements and brand investments to offset pressures.